目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study design
1.1.3. Indication
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Phase outlook
2.2.2. Study design outlook
2.2.3. Indication outlook
2.3. Competitive Insights

Chapter 3. Indian Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Indian Clinical Trials Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. Indian Clinical Trials: Phase Estimates & Trend Analysis
4.1. Indian Clinical Trials Market: Key Takeaways
4.2. Indian Clinical Trials Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Phase I
4.3.1. Phase I market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Phase ll
4.4.1. Phase ll market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Phase lll
4.5.1. Phase lll market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Phase lV
4.6.1. Phase lV market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Indian Clinical Trials: Study Design Estimates & Trend Analysis
5.1. Indian Clinical Trials Market: Key Takeaways
5.2. Indian Clinical Trials Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Interventional Trials
5.3.1. Interventional trials market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Observational Trials
5.4.1. Observational trials market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Expanded Access Trials
5.5.1. Expanded access trials market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Indian Clinical Trials: Indication Estimates & Trend Analysis
6.1. Indian Clinical Trials Market: Key Takeaways
6.2. Indian Clinical Trials Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Autoimmune/Inflammation
6.3.1. Autoimmune/inflammation market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.2. Rheumatoid arthritis
6.3.2.1. Rheumatoid arthritis market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.3. Multiple sclerosis
6.3.3.1. Multiple sclerosis market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.4. Osteoarthritis
6.3.4.1. Osteoarthritis market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.5. Irritable bowel syndrome (IBS)
6.3.5.1. Irritable bowel syndrome (IBS) market estimates and forecasts, 2018 to 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Pain Management
6.4.1. Pain management market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.2. Chronic pain
6.4.2.1. Chronic pain market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. Acute pain
6.4.3.1. Acute pain market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Oncology
6.5.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.2. Blood cancer
6.5.2.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.3. Solid tumors
6.5.3.1. Solid tumors market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.4. Others
6.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. CNS Condition
6.6.1. CNS condition market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.2. Epilepsy
6.6.2.1. Epilepsy market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.3. Parkinson’s disease
6.6.3.1. Parkinson’s disease market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.4. Huntington’s disease
6.6.4.1. Huntington’s disease market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.5. Stroke
6.6.5.1. Stroke market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.6. Traumatic brain injury
6.6.6.1. Traumatic brain injury market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.7. Amyotrophic lateral sclerosis
6.6.7.1. Amyotrophic lateral sclerosis market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.8. Muscle regeneration
6.6.8.1. Muscle regeneration market estimates and forecasts, 2018 to 2030 (USD Million)
6.6.9. Others
6.6.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Diabetes
6.7.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Obesity
6.8.1. Obesity market estimates and forecasts, 2018 to 2030 (USD Million)
6.9. Cardiovascular
6.9.1. Cardiovascular market estimates and forecasts, 2018 to 2030 (USD Million)
6.10. Others
6.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. IQVIA holdings Inc. (QUintilesIMS)
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Paraxel International Corporation
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Pharmaceutical Product Development, LLC
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Charles River Laboratory
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. ICON plc
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. PRA Health Sciences, INC.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Chiltern International Ltd. (Covance Inc.)
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Syneos Health Inc. (inc research)
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. SGS SA
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Syngene International Limited
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Aurigene Discovery Technologies Limited
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Aragen Life Sciences
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Abiogenesis Clinpharm Pvt Ltd
7.2.13.1. Accelsiors Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Accelsiors
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Accutest Global
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. Clario
7.2.16.1. Company overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives
7.2.17. Cliantha Research
7.2.17.1. Company overview
7.2.17.2. Financial performance
7.2.17.3. Product benchmarking
7.2.17.4. Strategic initiatives
7.2.18. Cliniminds
7.2.18.1. Company overview
7.2.18.2. Financial performance
7.2.18.3. Product benchmarking
7.2.18.4. Strategic initiatives
7.2.19. CliniRx
7.2.19.1. Company overview
7.2.19.2. Financial performance
7.2.19.3. Product benchmarking
7.2.19.4. Strategic initiatives
7.2.20. JSS Medical Research
7.2.20.1. Company overview
7.2.20.2. Financial performance
7.2.20.3. Product benchmarking
7.2.20.4. Strategic initiatives

List of Tables
Table 1 List of Abbreviations
Table 2 India clinical trials market, by phase, 2018 - 2030 (USD Million)
Table 3 India clinical trials market, by study design, 2018 - 2030 (USD Million)
Table 4 India clinical trials market, by indication, 2018 - 2030 (USD Million)

List of Figure

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Indian clinical trials: Market outlook
Fig. 9 Indian clinical trials: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Indian clinical trials market driver impact
Fig. 15 Indian clinical trials market restraint impact
Fig. 16 Indian clinical trials market strategic initiatives analysis
Fig. 17 Indian clinical trials market: Phase movement analysis
Fig. 18 Indian clinical trials market: Phase outlook and key takeaways
Fig. 19 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Indian clinical trials market: Study design movement analysis
Fig. 24 Indian clinical trials market: Study design outlook and key takeaways
Fig. 25 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Indian clinical trials market: Indication movement analysis
Fig. 29 Indian clinical trials market: Indication outlook and key takeaways
Fig. 30 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Irritable bowel syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Pain management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 CNS Conditions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Parkinson's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Huntington's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Traumatic brain injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Amyotrophic lateral sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 India market estimates and forecasts, 2018 - 2030 (USD Million)